A research team at MedUni Vienna developed a method which utilizes multi-omics and machine learning to identify prostate cancer patients for whom surgical treatment is the best option, potentially avoiding unnecessary surgery in patients with a lower risk of tumor spread.
The phase II DESTINY-CRC02 trial has identified the preferred dosage of single-agent fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive advanced colorectal cancer.
The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.
FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous injection.
FDA has granted orphan drug designation for the GSK-3β inhibitor elraglusib, for treatment of soft tissue sarcoma.
FDA is seeking consumer representatives to serve on the Oncologic Drugs Advisory Committee.
Astera Cancer Care, a partner of the One Oncology Network, has partnered with Knowtex to develop advanced voice and generative AI workflows tailored specifically for oncology.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.
A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.
